66 Hudson Boulevard East
New York, NY 10001-2192

URGENT: DRUG RECALL

September 4, 2026

Dopamine HCl Injection, USP

Carton NDC	Vial NDC	Lot Number	Expiration Date	Strength	Configuration/Count
0409-5820-01	0409-5820-11	NL5230	2027-OCT	200 mg/5 mL (40 mg/mL)	25 vials per tray

Dear Customer:

Hospira, Inc., a Pfizer company, is voluntarily recalling the above referenced lot of **Dopamine HCl Injection, USP**. Pfizer initiated this recall due to a GMP deviation during manufacturing where there was potential product exposure to extrinsic particles and impurities.

Pfizer has completed a Health Hazard Assessment which concluded that the overall potential risk to the patient arising from this issue is considered to be low. The use of impacted product has a potential of being associated with adverse events which could be serious to critical in severity, such as reduced therapeutic effectiveness, toxicity, allergic reactions, vascular occlusion, pulmonary embolism, inflammation, phlebitis, thrombophlebitis, or microvascular tissue injury.

To date, Pfizer has not received reports of any adverse events associated with this issue.

FEDERAL REGULATION 21 CFR 7.49 (d) RESPONSIBILITY OF RECIPIENT STATES: "CONSIGNEES THAT RECEIVE A RECALL COMMUNICATION SHOULD IMMEDIATELY CARRY OUT THE INSTRUCTIONS SET FORTH BY THE RECALLING FIRM …" PFIZER RECOMMENDS THAT YOU RESPOND TO THIS RECALL EVEN IF YOU DO NOT HAVE THE RECALLED PRODUCT. TO RESPOND, COMPLETE THE REQUESTED INFORMATION ON THE ENCLOSED BUSINESS REPLY FORM (BRF) AND RETURN IT, AS DIRECTED, WITHIN FIVE (5) BUSINESS DAYS. If you have any questions about responding to this letter, please contact Sedgwick at 1-888-943-2397 (Mon.-Fri. 8 am-5 pm ET).

The recall of the above referenced lot of **Dopamine HCl Injection, USP** is being conducted to the **Retail** level.

Our records indicate that you received shipment of the affected product lot, which was distributed from **April 14, 2026 through August 12, 2026**. Please check your stock immediately against the table above. If you have any of the affected lot in your inventory, please discontinue use, stop distribution and quarantine the product immediately. Promptly return the product to Sedgwick; 2670 Executive Drive, Suite A; Indianapolis, IN 46241; Attn: Event 3806 using the enclosed pre-paid UPS label. **All returns are requested to be completed within six months of this notice date.** If you received this notification without the prepaid UPS label and BRF, require additional shipping labels, or have questions regarding the return procedure, please contact Sedgwick at 888-943-2397.

66 Hudson Boulevard East
New York, NY 10001-2192

If you have further distributed the recalled product, please notify your accounts and/or additional locations which may have received the recalled product. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution and quarantine the affected product. Promptly contact Sedgwick at 888-943-2397 (Mon.-Fri. 8 am-5 pm ET) to obtain pre-paid shipping labels to initiate the return process.

Reimbursement for the returned product will be made by credit memorandum. Please contact Pfizer Customer Service at 844-646-4398 (Mon.-Fri. 8 am-6 pm ET) or your Pfizer representative regarding product availability and questions regarding this market action.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. We appreciate your immediate attention and cooperation, and sincerely regret any inconvenience this action may cause you.

If you have any medical questions regarding the product, please call the appropriate contact center below.

Contact Center	Contact Information	Area of Support
Pfizer Medical Information	800-438-1985, option 3 (Mon.-Fri. 9 am-5 pm ET) www.pfizermedical.com	For medical questions regarding the product
Pfizer Drug Safety	800-438-1985, option 1 (24 hours a day; 7 days a week)	To report adverse events and product complaints

Sincerely,

Meera Bhavsar
U.S. Commercial Lead, Global Hospital & Biosimilars

66 Hudson Boulevard East
New York, NY 10001-2192

Please see Dopamine HCl Injection, USP, product label and photos below for ease in identifying the product: